Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.
Thomas P LodiseEngels N ObiAlexandre H WatanabeEmre YucelJae MinBrian H NathansonPublished in: The Journal of antimicrobial chemotherapy (2024)
Early treatment with ceftolozane/tazobactam may offer some clinical and cost benefits over ceftazidime/avibactam in patients with MDR-PSA PNA. Further large-scale studies are necessary to comprehensively understand the outcomes associated with these treatments for MDR-PSA PNA.
Keyphrases
- gram negative
- multidrug resistant
- acinetobacter baumannii
- drug resistant
- klebsiella pneumoniae
- prostate cancer
- pseudomonas aeruginosa
- coronavirus disease
- sars cov
- cystic fibrosis
- type diabetes
- biofilm formation
- radical prostatectomy
- nucleic acid
- adipose tissue
- extracorporeal membrane oxygenation
- staphylococcus aureus
- acute respiratory distress syndrome
- glycemic control
- case control